Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Trial Profile

Open-Label Safety Study of ADS-5102 (Amantadine HCl) Extended Release Capsules for the Treatment of Levodopa Induced Dyskinesia (LID)

Status: Completed
Phase of Trial: Phase III

Latest Information Update: 04 Oct 2019

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Amantadine (Primary)
  • Indications Drug-induced dyskinesia
  • Focus Adverse reactions; Registrational
  • Acronyms EASE LID 2
  • Sponsors Adamas Pharmaceuticals
  • Most Recent Events

    • 09 May 2019 According to an Adamas Pharmaceuticals media release, new data from this Phase 3 open label study of GOCOVRI in Parkinsons patients with dyskinesia and OFF were presented at the American Academy of Neurology (AAN) in Philadelphia.
    • 09 Oct 2018 Results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders
    • 09 Oct 2018 Final safety results presented at the 22nd International Congress of Parkinson's Disease and Movement Disorders.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top